| Effect | None |
| Trial Design | Double blind |
| Trial Length | 1-6 months |
| Number of Subjects | 20 |
| Sex | Both Genders |
| Age Range | 18-29, 30-44, 45-64 |
| Body Types | Average |
The addition of 400 µg chromium (as picolinate) to antipsycotic therapy in a small sample of schizophrenic persons over three months failed to significantly influence symptoms of schizophrenia relative to control as assessed by PANSS and HAM-D rating scales.
